Tango Therapeutics

Approach
Pipeline
Leadership
Join Us
News + Events
Contact

Home
Our Approach
Pipeline
Leadership
Join Us
News + Events
Contact

EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer

Press Release

EGLN1 is a synthetic lethal target in ARID1A-mutant ovarian cancer

Tango Therapeutics
100 Binney Street, Suite 700
Cambridge, MA 02142
Tel: +1-857-320-4900

Contact
Careers